de Oliveira Claire, Cheng Joyce, Rehm Jürgen, Kurdyak Paul
a Centre for Addiction and Mental Health (CAMH).
b Institute for Clinical Evaluative Science (ICES) , Toronto , ON , Canada.
J Med Econ. 2018 Apr;21(4):348-355. doi: 10.1080/13696998.2017.1412976. Epub 2017 Dec 20.
Previous work found that, among high-cost patients, those with a majority of mental health and addiction (MHA)-related costs (>50%) incur over 30% more costs than other high-cost patients. However, this work did not examine other high-cost patients in depth or whether they had any MHA-related costs. The objective of this analysis was to examine the role of MHA-related care among other high-cost patients.
Using administrative healthcare data from Ontario, Canada, this study selected all patients in the 90th percentile of the cost distribution in 2012. It focused primarily on two groups based on the percentage of MHA-related costs relative to total costs: (1) high-cost patients with some MHA-related costs (0% > and <50%) and (2) high-cost patients with no MHA-related costs (0%). We examined socio-demographic and clinical characteristics, utilization and costs for both groups, and modeled patient-level costs using appropriate regression techniques. We also compared these groups with high-cost patients with a majority of MHA-related costs (>50%).
High-cost patients with some MHA-related costs incurred over 40% more costs than those without ($27,883 vs $19,702). Patients with some MHA-related costs were older, lived in poorer neighborhoods, and had higher levels of comorbidity compared to those without. After controlling for relevant variables, having any type of MHA-related utilization increased costs by $2,698. Having a diagnosis of psychosis had a large impact on costs.
This study did not examine children and adolescents. We were only able to account for 91% of all costs incurred by the public third-party payer; addiction-related costs from community-based agencies were not available.
High-cost patients with MHA incur higher costs compared to those without. When considering interventions aimed at high-cost patients, policy-makers should consider their complex nature, specifically both their physical and MHA-related comorbidities.
先前的研究发现,在高成本患者中,那些心理健康和成瘾(MHA)相关成本占多数(>50%)的患者比其他高成本患者的成本高出30%以上。然而,这项研究没有深入研究其他高成本患者,也没有研究他们是否有任何与MHA相关的成本。本分析的目的是研究MHA相关护理在其他高成本患者中的作用。
本研究使用加拿大安大略省的行政医疗保健数据,选取了2012年成本分布处于第90百分位的所有患者。它主要基于MHA相关成本占总成本的百分比关注两组患者:(1)有一些MHA相关成本(0%>且<50%)的高成本患者和(2)没有MHA相关成本(0%)的高成本患者。我们研究了两组患者的社会人口统计学和临床特征、医疗服务利用情况和成本,并使用适当的回归技术对患者层面的成本进行建模。我们还将这些组与MHA相关成本占多数(>50%)的高成本患者进行了比较。
有一些MHA相关成本的高成本患者比没有此类成本的患者成本高出40%以上(27,883美元对19,702美元)。与没有MHA相关成本的患者相比,有一些MHA相关成本的患者年龄更大,居住在更贫困的社区,合并症水平更高。在控制相关变量后,任何类型的MHA相关医疗服务利用都会使成本增加2,698美元。患有精神病对成本有很大影响。
本研究未考察儿童和青少年。我们仅能解释公共第三方支付者产生的所有成本的91%;来自社区机构的成瘾相关成本不可用。
与没有MHA相关成本的患者相比,有MHA相关成本的高成本患者成本更高。在考虑针对高成本患者的干预措施时,政策制定者应考虑他们的复杂性质,特别是他们的身体和与MHA相关的合并症。